نتایج جستجو برای: hematologic neoplasms

تعداد نتایج: 507542  

2014
J. Maerki G. Katava D. Siegel J. Silberberg P. K. Bhattacharyya

Background. Multiple articles discuss the rare incidence and potential causes of second hematologic disorders arising after treatment of Chronic Myelogenous Leukemia (CML), leading to the theory of imatinib, the current treatment regimen for CML, as a possible trigger for the development of secondary neoplasms. Our case eliminates the possibility of imatinib as the sole cause since our patient ...

2017
Habip Gedik

Background Most frequently, empirical antibiotic therapy is immediately administered for patients with febrile neutropenia (FN). In this study, its aim was to assess the antibiotic resistance status and the cost of antibacterial agents in FN patients associated with hematological malignancies. Methods The cost of antibacterial agents used in FN episodes in patients with hematologic neoplasms ...

2012
Apollina Goel

Multiple myeloma (MM) is a malignant neoplasm of plasma cells that constitutes 1% of all cancers and 10% of hematologic neoplasms. MM is the second most common hematologic malignancy after nonHodgkin’s lymphoma. It is estimated that 21,700 new cases of MM (approximately 12,190 men and 9,510 women) will be diagnosed during 2012 in the United States, and approximately 10,710 individuals (6,020 me...

2014
Sara C. Meyer Ross L. Levine

Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways. Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK–STAT signaling is associated with hematologic malignancies, autoimmune disorders, and immune-deficient condition...

Journal: :Blood 2005
Marco Ladetto Sonia Vallet Andreas Trojan Maria Dell'Aquila Luigia Monitillo Rosalba Rosato Loredana Santo Daniela Drandi Alessandra Bertola Patrizia Falco Federica Cavallo Irene Ricca Federica De Marco Barbara Mantoan Beata Bode-Lesniewska Gloria Pagliano Roberto Francese Alberto Rocci Monica Astolfi Mara Compagno Sara Mariani Laura Godio Lydia Marino Marina Ruggeri Paola Omedè Antonio Palumbo Mario Boccadoro

Cyclooxygenase 2 (COX-2) is an inflammation-associated enzyme involved in the pathogenesis of many solid tumors, but little is known about its presence and role in hematologic neoplasms. Multiple myeloma (MM) is known to involve a deregulated cytokine network with secretion of inflammatory mediators. We thus decided to investigate the involvement of COX-2 in this neoplasm. Western blotting (WB)...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
Sara C Meyer Ross L Levine

Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways. Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK-STAT signaling is associated with hematologic malignancies, autoimmune disorders, and immune-deficient condition...

2008
J. DEPUE JOSEPH M. TUSCANO G. STEFANACCI

Journal: :Blood 1990
R A Brown R H Herzig S N Wolff D Frei-Lahr L Pineiro B J Bolwell J N Lowder E A Harden K R Hande G P Herzig

Seventy-five patients with resistant acute leukemia or lymphoma received high-dose cyclophosphamide and etoposide to explore the activity of this combination in resistant hematologic malignancies, and to determine the maximum doses of these drugs that can be combined without bone marrow transplantation. Etoposide was administered over 29 to 69 hours by continuous infusion corresponding to total...

Journal: :Oncology 2008
Panagiotis Samaras Stefan Dold Julia Braun Peter Kestenholz Stefan Breitenstein Alexander Imhof Christoph Renner Frank Stenner-Liewen Bernhard C Pestalozzi

BACKGROUND We assessed longevity and complications of totally implantable venous access devices in oncology patients. METHODS 197 patients received a total of 201 port devices via the subclavian vein for delivery of chemotherapy between January 1, 2005, and December 31, 2006. We reviewed the patient charts for port-related complications and risk factors until July 31, 2007. RESULTS A total ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید